AgeX Therapeutics, Inc. AGE
Mar 26, 2024, 3:59 PM EDT
52-week range unavailable
- Market cap
- 27.76M
- Revenue (ttm)
- 142.00K
- Shares out
- 2.50M
- Volume
- 3.68K
- Open
- 12.59
- Previous close
- 11.10
- Day's range
- 11.10 – 12.59
- Beta
- 1.19
2Y -19.84 (-64.12%)
Key statistics
- Enterprise value
- 31.67M
- PEG ratio
- 0.00
- Price / sales
- 195.48
- Price / book
- 2.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 600.00%
- Free cash flow
- -2.01M
- Total cash
- 345.00K
- Total debt
- 4.37M
- Return on equity
- 0.00%
- Short % of float
- 0.01%
- 50-day average
- 13.98
- 200-day average
- 19.89
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About AgeX Therapeutics, Inc.
As of March 26, 2024, AgeX Therapeutics, Inc. was acquired by Serina Therapeutics, Inc., in a reverse merger transaction. AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- agexinc.com
News
Your note
Sign in to keep a note on AGE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JUVENESCENCE LTD. | Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Mar 13, 2023 | 16,447,500 |
| WEST MICHAEL D | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 9, 2023 | 41,982 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Broadwood Capital, Inc. | 7.90% | 2,997,156 | 2.68M | Jun 29, 2023 |
| Vanguard Group Inc | 1.84% | 698,414 | 623.82K | Jun 29, 2023 |
| Prescott General Partners LLC | 0.49% | 185,185 | 165.41K | Jun 29, 2023 |
| Bridgeway Capital Management, Inc. | 0.38% | 144,770 | 129.31K | Jun 29, 2023 |
| Sigma Planning Corp | 0.37% | 139,700 | 124.78K | Jun 29, 2023 |
| Blackrock Inc. | 0.35% | 131,844 | 117.76K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.12% | 426,190 | 380.67K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.68% | 259,263 | 231.57K | Jun 29, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.37% | 140,000 | 125.05K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.16% | 59,696 | 29.85K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.06% | 24,431 | 12.21K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.03% | 10,213 | 5.11K | May 30, 2023 |